Logo

GPC, Atugen Link Platforms For Genomics, Proteomics

Mar 10, 2000
Premium

B

ERLIN--GPC, a genomics-based drug discovery company headquartered in Munich, and Atugen, a target discovery and validation company here, announced a strategic alliance to provide life sciences companies with an integrated functional genomics and proteomics platform to identify and validate novel drug discovery targets. The combined technology platforms can be applied to major diseases such as cancer and metabolic disorders as well as central nervous system and heart ailments.

Filed under

Informatics
Breaking News
The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.